Phase 2 N=39 A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
Ovarian Cancer
Primary: Time to Recurrence (TTR) — 18.2; 12.4 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=260 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen — 17.8 percentage of participants
N/A N=40 A Rehabilitation Tool to Determine Patient's Stay in Hospital After Joint Replacement
Total Joint Replacement Surgery
Primary: Length of Stay in Hospital Through Discharge — 3 days
Phase 2 N=388 Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
Metastatic Castration-resistant Prostate Cancer
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort 1, Cohort 2, Cohort 4 and Cohorts 1 and 2 Combined) — 6.0; 3.0; 12.3…
Phase 2 N=16 Soluble Epoxide Hydrolase Inhibition and Insulin Resistance
Diabetes Mellitus · Endocrine System Diseases · Glucose Metabolism Disorders
Primary: Insulin Sensitivity — 12.0; 11.6 mg/kg/FFM/min — p=0.71
Phase 3 N=112 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Lung Neoplasms · Lung Cancer
Primary: Clinically Significant Events (CSE) — .530 proportion of participants
N/A N=34 Feasibility of At-Home Telehealth Yoga for Treating Chronic Pain
Chronic Pain · Musculoskeletal Pain
Primary: Multi-Dimensional Treatment Satisfaction Measure — 3.2; 3.6 score on a scale
Phase 2 N=9 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Clinical Stage IV Gastric Cancer AJCC v8 · Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage IVA Gastric Cancer AJCC v8
Primary: Progression-free Survival — 1.1 Months
N/A N=606 Stress, Sex, and the Generalization of Fear
Psychological Stress
Primary: Fear-potentiated Startle Responses to the CS+ and CS- During Acquisition — 52.059; 19.162; 44.388; 9.732 Fear-potentiated startle (microvolts) — p=0.453
Phase 2 N=71 The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
SARS-CoV 2
Primary: Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801 — 0; 4; 10; 7 Participants
N/A N=33 Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
Type 1 Diabetes Mellitus
Primary: Glucose Variability (Coefficient of Variation) — 0.33; 0.36; 0.3; 0.34 coefficient of variation — p=0.045
Phase 1 N=47 A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan — 140; 123; 124 nanograms per milliliter (ng/mL)
N/A N=18 How do You Take Your Coffee Before Anesthesia
Anesthesia · Aspiration · Fasting
Primary: Difference Between Gastric Volume Post Coffee Consumption Compared to the Baseline Gastric Volume — 13; 5; -1.5 milliliters
Phase 2 N=23 Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
CLL · Leukemia
Primary: Number of Participants With a Response — 12 Participants
Phase 2 N=20 Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Soft-tissue Sarcomas
Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2